1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Heart Disease, Ischemic in 13 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We sought to determine whether a potent Rho-kinase inhibitor fasudil prevents the occurrence of myocardial ischemia in patients with microvascular angina attributable to coronary microvascular spasm." | 9.10 | Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. ( Hirakawa, Y; Masumoto, A; Mohri, M; Shimokawa, H; Takeshita, A, 2003) |
| ", M/F 26/10) who underwent intracoronary administration of fasudil during a procedure to resolve myocardial ischemia that was resistant to intracoronary nitrate administration." | 7.91 | Usefulness of intracoronary administration of fasudil, a selective Rho-kinase inhibitor, for PCI-related refractory myocardial ischemia. ( Hao, K; Ikeda, S; Kikuchi, Y; Matsumoto, Y; Miyata, S; Sakata, Y; Sato, K; Shimokawa, H; Shindo, T; Shiroto, T; Suda, A; Sugisawa, J; Takahashi, J; Tsuchiya, S, 2019) |
| " This study aimed to determine the protective effect of fasudil pretreatment combined with IPO on myocardial ischemia/reperfusion injury in rats and explore the possible mechanisms." | 7.80 | The protective effect of fasudil pretreatment combined with ischemia postconditioning on myocardial ischemia/reperfusion injury in rats. ( Guan, YE; Jia, DL; Li, WN; Shu, WQ; Wu, N, 2014) |
| "We sought to determine whether a potent Rho-kinase inhibitor fasudil prevents the occurrence of myocardial ischemia in patients with microvascular angina attributable to coronary microvascular spasm." | 5.10 | Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. ( Hirakawa, Y; Masumoto, A; Mohri, M; Shimokawa, H; Takeshita, A, 2003) |
| ", M/F 26/10) who underwent intracoronary administration of fasudil during a procedure to resolve myocardial ischemia that was resistant to intracoronary nitrate administration." | 3.91 | Usefulness of intracoronary administration of fasudil, a selective Rho-kinase inhibitor, for PCI-related refractory myocardial ischemia. ( Hao, K; Ikeda, S; Kikuchi, Y; Matsumoto, Y; Miyata, S; Sakata, Y; Sato, K; Shimokawa, H; Shindo, T; Shiroto, T; Suda, A; Sugisawa, J; Takahashi, J; Tsuchiya, S, 2019) |
| " This study aimed to determine the protective effect of fasudil pretreatment combined with IPO on myocardial ischemia/reperfusion injury in rats and explore the possible mechanisms." | 3.80 | The protective effect of fasudil pretreatment combined with ischemia postconditioning on myocardial ischemia/reperfusion injury in rats. ( Guan, YE; Jia, DL; Li, WN; Shu, WQ; Wu, N, 2014) |
| "Epicardial coronary stenosis causes myocardial ischemia; however, the role of coronary microvessels is poorly understood in the pathogenesis of effort angina." | 2.73 | Anti-ischemic effects of fasudil, a specific Rho-kinase inhibitor, in patients with stable effort angina. ( Fukumoto, Y; Hirakawa, Y; Hirooka, Y; Inokuchi, K; Ito, A; Masumoto, A; Mohri, M; Shimokawa, H; Takeshita, A, 2007) |
| "Adenosine acts as a cardioprotective agent by producing coronary vasodilation, decreasing heart rate and by antagonizing the cardiostimulatory effect of catecholamines; adenosine also exerts a direct negative inotropic effect." | 1.31 | Adenosine induced direct negative inotropic effect is abolished during global ischemia: role of protein kinase C and prostacyclin. ( Oriji, GK, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 8 (61.54) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, Z | 1 |
| Qiu, B | 1 |
| Wang, Q | 1 |
| Wei, W | 1 |
| Huang, J | 1 |
| Duan, W | 1 |
| Miyahara, S | 1 |
| Jenke, A | 1 |
| Yazdanyar, M | 1 |
| Kistner, J | 1 |
| Immohr, MB | 1 |
| Sugimura, Y | 1 |
| Aubin, H | 1 |
| Kamiya, H | 1 |
| Okita, Y | 1 |
| Lichtenberg, A | 1 |
| Akhyari, P | 1 |
| Kikuchi, Y | 1 |
| Takahashi, J | 1 |
| Hao, K | 1 |
| Sato, K | 1 |
| Sugisawa, J | 1 |
| Tsuchiya, S | 1 |
| Suda, A | 1 |
| Shindo, T | 1 |
| Ikeda, S | 1 |
| Shiroto, T | 1 |
| Matsumoto, Y | 1 |
| Miyata, S | 1 |
| Sakata, Y | 1 |
| Shimokawa, H | 4 |
| Li, WN | 1 |
| Wu, N | 1 |
| Shu, WQ | 1 |
| Guan, YE | 1 |
| Jia, DL | 1 |
| Jawad, E | 1 |
| Arora, R | 1 |
| Mohri, M | 2 |
| Hirakawa, Y | 2 |
| Masumoto, A | 2 |
| Takeshita, A | 2 |
| Nishizawa, K | 1 |
| Wolkowicz, PE | 1 |
| Yamagishi, T | 1 |
| Guo, LL | 1 |
| Pike, MM | 1 |
| Vincelette, J | 1 |
| Pagila, R | 1 |
| Kawai, K | 1 |
| Ishii, M | 1 |
| Horimizu, Y | 1 |
| Vergona, R | 1 |
| Sullivan, ME | 1 |
| Morser, J | 1 |
| Dole, WP | 1 |
| Wang, YX | 1 |
| Fukumoto, Y | 1 |
| Inokuchi, K | 1 |
| Ito, A | 1 |
| Hirooka, Y | 1 |
| Przyklenk, K | 1 |
| Sussman, MA | 1 |
| Simkhovich, BZ | 1 |
| Kloner, RA | 1 |
| Yamamoto, Y | 1 |
| Ikegaki, I | 2 |
| Sasaki, Y | 1 |
| Uchida, T | 1 |
| Oriji, GK | 1 |
| Utsunomiya, T | 1 |
| Satoh, S | 1 |
| Toshima, Y | 1 |
| Asano, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation[NCT02338232] | 32 participants (Actual) | Interventional | 2015-07-07 | Terminated (stopped due to Lack of Accrual) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Heart Disease, Ischemic
| Article | Year |
|---|---|
Chronic stable angina pectoris.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetanilides; Angina Pectoris; Antihypertensive Agent | 2008 |
2 trials available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Heart Disease, Ischemic
| Article | Year |
|---|---|
Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetylcholine; Aged; Cardiovascular Agents; Coronary | 2003 |
Anti-ischemic effects of fasudil, a specific Rho-kinase inhibitor, in patients with stable effort angina.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Angina Pectoris; Cardiac Pacing, Artificial; Co | 2007 |
10 other studies available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Heart Disease, Ischemic
| Article | Year |
|---|---|
Fasudil on Myocardial Injury in Rats with Myocardial Ischemia and Reperfusion through Rho-ROCK Signal Pathway.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Coronary Artery Disease; Humans; Ischemia; M | 2022 |
The combination approach with Rhokinase inhibition and mechanical circulatory support in myocardial ischemia-reperfusion injury: Rho-kinase inhibition and ventricular unloading.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Coronary Artery Disease; Humans; Male; Myoca | 2022 |
Usefulness of intracoronary administration of fasudil, a selective Rho-kinase inhibitor, for PCI-related refractory myocardial ischemia.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Female; Humans; Male; Middle Aged; Myocardial I | 2019 |
The protective effect of fasudil pretreatment combined with ischemia postconditioning on myocardial ischemia/reperfusion injury in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cardiotonic Agents; Combined Modality Therap | 2014 |
Fasudil prevents KATP channel-induced improvement in postischemic functional recovery.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Heart; In Vitro Techniques; Magnetic Resonan | 2005 |
Inhibition of rho-kinase by hydroxyfasudil prevents vasopressin-induced myocardial ischemia in Donryu rats by attenuating coronary vasoconstriction.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Arginine Vasopressin; Blood Pressure; Electr | 2005 |
Does ischemic preconditioning trigger translocation of protein kinase C in the canine model?
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Biological Transport; Coronary Circulation; | 1995 |
The protein kinase inhibitor fasudil protects against ischemic myocardial injury induced by endothelin-1 in the rabbit.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cell Movement; Diltiazem; Electrocardiograph | 2000 |
Adenosine induced direct negative inotropic effect is abolished during global ischemia: role of protein kinase C and prostacyclin.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adenosine; Animals; Depression, Chemical; Drug Intera | 2000 |
Antianginal effects of hydroxyfasudil, a Rho-kinase inhibitor, in a canine model of effort angina.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Anesthesia; Angina Pectoris; Animals; Cardiac Pacing, | 2001 |